Head-to-head evidence
HS-20094 vs NNC0519-0130
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/GIP receptor (dual) · full Obesity pipeline
HS-20094
Developed by Hansoh Pharmaceutical Group
NCT06839664 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial (n=604). The co-primary endpoints, percent weight change and the proportion achieving at least 5% weight loss at week 48, were both met: participants lost up to 19.3% of body weight and up to 97.2% achieved at least 5% weight loss, both significantly better than placebo.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: November 2026 · NCT07431086 (registry estimate)
NNC0519-0130
Developed by Novo Nordisk
NCT06326060 · Phase 2 · completed
The study was randomized and quadruple-blind, included placebo and active-comparator arms, and enrolled 354 participants; its primary endpoint was the clinical measure of relative body-weight change. Because the registry does not report whether this endpoint was met, the findings cannot currently support the highest evidence grade.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HS-20094's landscape · NNC0519-0130's landscape